Cas:726-37-4 N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline manufacturer & supplier

Chemical Name:N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline

CAS.NO:726-37-4

Synonyms:MFCD00192071

Molecular Formula:C₁₅H₁₆N₂

Molecular Weight:224.30100

HS Code:

Physical and Chemical Properties:

Melting point:135-138ºC (dec.)(lit.)

Boiling point:374.4ºC at 760 mmHg

Density:1.1g/cm3

Index of Refraction:1.668

PSA:16.13000

Exact Mass:224.13100

LogP:3.31800

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00192071 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00192071 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00192071 Use and application,MFCD00192071 technical grade,usp/ep/jp grade.

Related News: However, pharmaceutical intermediates are subdivided into primary intermediates and advanced intermediates. Because primary intermediate suppliers can only provide simple intermediate production, they are at the front end of the industrial chain. The pressure of competition and price is the greatest. The price fluctuations of basic chemical raw materials have a greater impact on them. N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline manufacturer Italy and Vietnam included Taiwan in banning flights from China, a move that they announced after the W.H.O. declared the coronavirus outbreak a global health emergency. N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline supplier The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline vendor The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. N,N-dimethyl-4-[(E)-2-pyridin-2-ylethenyl]aniline factory The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA.